Lorcaserin hailed as ‘holy grail’ in fight against obesity

A major study has found promising results for the safety of a weight-loss drug available online in the UK.

The study, published in the New England Journal of Medicine, says adults using the drug Lorcaserin lost an average of 4kg (8.8lb) over 40 months.

It says the drug, which works by suppressing appetite, does not put people at greater risk of heart issues.

But experts emphasise the importance of long-term lifestyle changes in achieving effective weight loss.

Lorcaserin has been available online in the US for several years under the name Belviq, but it has yet to be approved for use in Europe.

A weight-loss pill has been hailed as a potential “holy grail” in the fight against obesity after a major study showed it did not increase the risk of serious heart problems.

Researchers say lorcaserin is the first weight-loss drug to be deemed safe for heart health with long-term use. Taken twice a day, the drug is an appetite suppressant which works by stimulating brain chemicals to induce a feeling of fullness.

A US study saw 12,000 people who were either obese or overweight given the pills or a placebo – with those who took the drug shedding an average of 4kg (9lbs) in 40 months.

Further analysis showed no big differences in tests for heart valve damage.

Tam Fry, of Britain’s National Obesity Forum, said the drug is potentially the “holy grail” of weight-loss medicine.

“I think it is the thing everybody has been looking for,” he said.

“I think there will be several holy grails, but this is a holy grail and one which has been certainly at the back of the mind of a lot of specialists for a long time.

“But all of the other things apply – lifestyle change has got to be root and branch part of this.”

Prof Jason Halford, an obesity expert at the University of Liverpool, told the Daily Telegraph newspaper that the drug’s availability in the UK would depend on whether it is approved by National Health Service regulators.

“We don’t have any appetite suppressants available on the NHS. We have a massive great gap between lifestyle modification and surgery,” he said.

“At the moment you either get support and advice, or you get to surgery – there is nothing in between. This could be widely prescribed if it is approved by Nice (the National Institute of Health and Care Excellence) in the UK.”

The Food and Drug Administration, the US medicines watchdog, approved lorcaserin’s use in some adults in 2012.

The drug has been on sale there since 2013 under the name Belviq, where it costs $220- 290 (£155-225) a month.

The study into its long-term effects was led by Dr Erin Bohula, a cardiovascular medicine expert at the Harvard-affiliated Brigham and Women’s Hospital.

“Patients and their doctors have been nervous about using drugs to treat obesity and for good reason. There’s a history of these drugs having serious complications,” she said.

As well as affecting the heart, there are concerns weight-loss drugs can lead to mental health issues.

The results of the study into lorcaserin were discussed at the European Society of Cardiology in Munich on Sunday and have been published by the New England Journal of Medicine.

The researchers found after one year 39% of participants given lorcaserin had lost at least 5% of their starting weight, compared with 17% of those given placebo. Analysis also showed fewer people taking lorcaserin developed diabetes, 8.5% compared with 10.3% on placebo.

Tests for heart valve damage were done on 3,270 participants, but no significant differences in rates were identified.

Suicidal thoughts or behaviour were reported in 21 people taking lorcaserin compared with 11 people given placebo, however those taking the weight-loss drug had a history of depression.

The researchers said: “Among overweight or obese patients with atherosclerotic cardiovascular disease or multiple cardiovascular risk factors who were being treated with dietary and exercise interventions, those who received lorcaserin had better long-term rates of weight loss than those who received placebo at a median follow-up of 3.3 years.

“The higher weight-loss rates were achieved without an accompanying increase in the risk of cardiovascular events.”

Weight-Loss Drug Lorcaserin Clears Cardiovascular Safety Hurdle: CAMELLIA-TIMI 61

Whether the data are enough to change hearts and minds of doctors willing to prescribe the drug for modest weight loss is another question, however.

MUNICH, Germany—A drug already approved in the United States for weight loss in overweight and obese patients does not increase the risk of cardiovascular events, according to the results of a large safety study.

Importantly, in a subset of patients who underwent echocardiographic follow-up, CAMELLIA-TIMI 61 investigators did not observe any of the valve problems that have plagued anti-obesity agents in the past.

“The history with weight-loss agents has been very challenging,” lead investigator Erin Bohula, MD, DPhil (Brigham and Women’s Hospital, Boston, MA). “There have been a number approved for use and then found to have major safety signals and removed. And obesity is clearly a global problem—the rates overall have tripled in the last 40 years. In the US, for example, obesity rates are around 40% so it is a major problem. This is the first time in a rigorous outcomes study we’ve been able to document cardiovascular safety, and for that reason I think it is a milestone and it’s important for patients and providers.”

Presenting the results during a press conference at the European Society of Cardiology Congress 2018, Bohula said lifestyle modification remains the cornerstone of weight-loss therapy for all patients, but adherence is challenging. Having a safe pharmacologic agent is useful and a “step forward” in the field, she said.

Lorcaserin (Belviq, Eisai/Arena Pharmaceuticals), a selective agonist of 5-hydroxytryptamine 2C serotonin receptor (5-HT2C) that modulates appetite, was approved by the US Food and Drug Administration (FDA) in 2012 as an adjunct to a calorie-reduced diet and increased physical activity for weight management. In several trials to date—BLOSSOM, BLOOM, and BLOOM-Diabetes Mellitus—treatment with lorcaserin resulted in better sustained weight loss compared with placebo.

However, given the history of weight-loss drugs, particularly first-generation antiobesity agents such as dexfenfluramine and fenfluramine that increased the risk of pulmonary hypertension and valve problems, determining the long-term safety of lorcaserin was critical, according to investigators.

Other weight-loss agents have faced setbacks, too. Rimonabant was safe from a cardiovascular perspective, but was pulled from several markets, including Europe, because of serious neuropsychiatric side effects (it was never approved in the US), while a cardiovascular safety study testing a naltrexone/bupropion combination (Contrave, Takeda Pharmaceuticals), broke down over leaked interim results, although the drug remains on the market.

Modest Weight Loss With Lorcaserin

In the CAMELLIA-TIMI 61 study, which was presented as a late-breaking clinical trial and published August 26, 2018, in the New England Journal of Medicine, investigators randomized 12,000 overweight or obese patients with atherosclerotic cardiovascular disease or multiple cardiovascular risk factors to treatment with lorcaserin or placebo. Among the treated patients, 75% had established cardiovascular disease, 68% had coronary artery disease, and 40% had a prior MI. Additionally, 57% had diabetes mellitus, and nearly one-third were diagnosed with prediabetes.

The median weight and body mass index of the treated patients was 102 kg (224 lbs) and 35 kg/m2, respectively. After 1 year, weight loss in the lorcaserin- and placebo-treatment groups was 4.2 and 1.4 kg, respectively (P < 0.001). Overall, 38.7% and 14.6% of the lorcaserin-treated patients achieved a weight loss of at least 5% and 10% of their body weight, respectively, compared with 17.4% and 4.8% of patients in the placebo group, (P < 0.001 for both).

After 3.3 years of follow-up, major cardiovascular events—defined as cardiovascular death, MI, or stroke—occurred in 6.1% of the lorcaserin-treated patients and 6.2% of patients treated with placebo (HR 0.99; 95% CI 0.85-1.14). In an extended analysis of major cardiovascular events to include heart failure, unstable angina, or coronary revascularization, there was also no significant difference between the two treatment groups. Patients treated with lorcaserin were more likely to discontinue treatment, mainly because of headaches and nausea. There was no signal of cancer or serious neuropsychiatric side effects.

As part of the trial, investigators conducted an echocardiographic substudy in 3,270 patients to assess new or worsening FDA-defined valvulopathy at 1 year. Overall, there was no difference between the two study arms (1.8% with lorcaserin vs 1.3% in the placebo group; P = 0.24). None of the patients with valvulopathy were hospitalized or required treatment. The change in pulmonary artery systolic blood pressure at 1 year was also similar between the two groups.

To TCTMD, Bohula said that none of the 30 patients who developed valvulopathy in the study period with lorcaserin had symptoms or required valve repair or replacement. Moreover, the numerical increase in the lorcaserin arm was largely attributable to new-onset, mild aortic insufficiency. When compared with historical experience, Bohula said the development of symptomatic valve problems with prior agents typically occurred in the first year of treatment.

“At least the severity of what we’re seeing does not seem to correspond with what we’ve seen with the prior agents,” said Bohula.

Although the results are reassuring, Stephan Achenbach, MD (University of Erlangen, Germany), who chaired the press conference, said physicians have been burned by weight-loss agents in the past. Physicians don’t even know the details of the older trials, but the image of damaged valves is firmly lodged in their memory. “We’re so scared of the old drugs and valve damage,” he told TCTMD. “That’s what we all have in our minds. . . . So this is a relief. This is a drug that is safe.”

Kurt Huber, MD (Sigmund Freud University Medical School, Vienna, Austria), who was not involved in the study, also said the results are reassuring, but questioned whether the follow-up is sufficient to identify long-term side effects, particularly valve-related problems. “It’s safe for a bit more than 3 years,” he told TCTMD, “but what happens when we double the length of treatment?”

In an editorial, Julie Ingelfinger, MD, and Clifford Rosen, MD (Tufts University School of Medicine, Boston, MA), state that lorcaserin may be best used on a cautious basis according to the needs of individual patients. They advise continued follow-up, particularly since the drug is likely to be used for many years to maintain weight loss.

Potential Clinical Experiences

Speaking with the media, Bohula acknowledged that weight loss with lorcaserin is limited, especially when compared with bariatric surgery. In the first year, the between-group weight-loss difference was just 2.8 kg, but it was sustained during the 3.3 years follow-up. Trials to date with other weight-loss agents have only followed patients for 1 to 2 years, she said.

“It is modest, but it is something on top of diet and lifestyle, and it’s sustainable,” said Bohula. “And that’s the challenge—very often diet and lifestyle is not sustainable. We usually see some nadir in weight at 6 months and then people tend to regain [weight], and possibly regain [more] from where they started out. So something that helps maintain that weight loss for a longer period of time is something that moves the needle.”

To TCTMD, Huber cautioned that the modest weight loss was largely observed in the first year and the clinical significance of the change is unknown. “The drug supports things, but it doesn’t really help to lose weight in the range that is necessary,” said Huber. Lifestyle, he suggested, really needs to be altered for significant weight loss so a drug that helps patients lose weight in the first year could help patients get more active to make more sustained long-term changes. “Whether you should take it for a very long time is another question,” he said.

For Achenbach, it was slightly disappointing that treatment with lorcaserin didn’t lower the risk of cardiovascular events given the weight loss. “Is this a cosmetic drug now? It makes you thinner, but it doesn’t lower your risk of heart attack,” he commented to TCTMD. “Maybe we need to wait longer? Maybe the positive cardiovascular effects won’t occur in 3 years, but maybe they’ll take 5 or 10 years before they occur.”

Based on CAMELLIA-TIMI 61, Achenbach said he is comfortable enough with the safety data to keep a patient on lorcaserin if they were taking it, but he wouldn’t start a patient on the drug given the modest weight loss and absence of cardiovascular benefit. In addition to weight loss, Bohula noted there were improvements in systolic blood pressure, heart rate, and a 19% reduction in new-onset diabetes. The full metabolic data will be presented next month at the European Association for the Study of Diabetes (EASD) meeting in Berlin, Germany.

In the United States, weight-loss agents, including lorcaserin, are used infrequently, largely stemming from the poor safety profiles and/or lack of data. Without evidence of safety, physicians are reluctant to prescribe the drugs—they know the history and it scares them, said Bohula—and patients are reluctant to take them.

“I think these are important findings, where we can now confidently say that [lorcaserin] is safe in terms of major adverse cardiovascular events,” said Bohula. “I suspect there might be physicians and patients who are more inclined to use this pharmacologic agent going forward.”

Sources
  1. Bohula EA, Wiviott SD, McGuire DK, et al. Cardiovascular safety of lorcasersin in overweight or obese patients . N Engl J Med. 2018
  2. Ingelfinger JR, Rosen CJ. Lorcaserin—elixir or liability. N Engl J Med. 2019;
  3. Obesity and overweight fact sheet. Geneva: World Health Organization, 2016(http://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight).  Google Scholar
  4. Hales CM, Fryar CD, Carroll MD, Freedman DS, Ogden CL. Trends in obesity and severe obesity prevalence in US youth and adults by sex and age, 2007-2008 to 2015-2016. JAMA 2018;319:17231725.
  5. The GBD 2015 Obesity Collaborators. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med 2017;377:1327Web of Science  / Medline  / Google Scholar
  6. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA 2013;309:7182Crossref / Web of ScienceMedlineGoogle Scholar
  7. Bray GA, Heisel WE, Afshin A, et al. The science of obesity management: an Endocrine Society scientific statement. Endocr Rev 2018; 39:79132CrossrefMedlineGoogle Scholar
  8. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Obesity Society. Circulation 2014;129:Suppl 2:S102S138. CrossrefWeb of ScienceMedlineGoogle Scholar
  9. Garvey WT, Garber AJ, Mechanick JI, et al. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. Endocr Pract 2014;20:977989CrossrefMedlineGoogle Scholar
  10. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine–phentermine. N Engl J Med 1997;337:581588Full TextWeb of ScienceMedlineGoogle Scholar
  11. James WPT, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010;363:905917Full TextWeb of ScienceMedlineGoogle Scholar
  12. Topol EJ, Bousser MG, Fox KA, et al. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet 2010;376:517523CrossrefMedlineGoogle Scholar
  13. Brashier DB, Sharma AK, Dahiya N, Singh SK, Khadka A. Lorcaserin: a novel antiobesity drug. J Pharmacol Pharmacother 2014;5:175178CrossrefMedlineGoogle Scholar
  14. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010;363:245256Full TextWeb of ScienceMedlineGoogle Scholar
  15. Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 2011;96:30673077CrossrefMedlineGoogle Scholar
  16. O’Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring) 2012;20:14261436CrossrefWeb of ScienceMedlineGoogle Scholar
  17. Bohula EA, Scirica BM, Fanola C, et al. Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial. Am Heart J 2018;202:3948CrossrefMedlineGoogle Scholar
  18. Leblanc ES, O’Connor E, Whitlock EP, Patnode CD, Kapka T. Effectiveness of primary care-relevant treatments for obesity in adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2011;155:434447CrossrefMedlineGoogle Scholar
  19. Hiatt WR, Thomas A, Goldfine AB. What cost weight loss? Circulation 2012;125:11711177CrossrefMedlineGoogle Scholar
  20. Nissen SE, Wolski KE, Prcela L, et al. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. JAMA 2016;315:9901004CrossrefMedlineGoogle Scholar
  21. Vorsanger MH, Subramanyam P, Weintraub HS, et al. Cardiovascular effects of the new weight loss agents. J Am Coll Cardiol 2016;68:849859CrossrefMedlineGoogle Scholar
  22. Jordan J, Astrup A, Engeli S, Narkiewicz K, Day WW, Finer N. Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity. J Hypertens 2014;32:11781188CrossrefMedlineGoogle Scholar
  23. Sjöström L, Narbro K, Sjöström CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007;357:741752Full TextWeb of ScienceMedlineGoogle Scholar
  24. Guidance for industry: developing products for weight management. Rockville, MD: Food and Drug Administration, 2007 (https://www.fda.gov/downloads/Drugs/Guidances/ucm071612.pdf / ). Google Scholar
  25. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311322Full TextWeb of ScienceMedlineGoogle Scholar
  26. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012;307:5665CrossrefWeb of ScienceMedlineGoogle Scholar
  27. Sundström J, Bruze G, Ottosson J, Marcus C, Näslund I, Neovius M. Weight loss and heart failure: a nationwide study of gastric bypass surgery versus intensive lifestyle treatment. Circulation 2017;135:15771585CrossrefMedlineGoogle Scholar
  28. Zhou X, Yu J, Li L, et al. Effects of bariatric surgery on mortality, cardiovascular events, and cancer outcomes in obese patients: systematic review and meta-analysis. Obes Surg 2016;26:25902601CrossrefMedlineGoogle Scholar
  29. The Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013;369:145154Web of ScienceMedlineGoogle Scholar
  30. Meltzer HY, Roth BL. Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs. J Clin Invest 2013;123:49864991CrossrefMedlineGoogle Scholar
  31. Thomsen WJ, Grottick AJ, Menzaghi F, et al. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther 2008;325:577587CrossrefWeb of ScienceMedlineGoogle Scholar
  32. Hales CM, Fryar CD, Carroll MD, Freedman DS, Ogden CL. Trends in obesity and severe obesity prevalence in US youth and adults by sex and age, 2007-2008 to 2015-2016. JAMA 2018;319:17231725Crossref

 

 

 

 

Slim Fizz

Slim Fizz is effervescent tablets for weight loss that have become popular in the UK since July 2015. The first reviews about Slim Fizz were published in the British tabloid Daily Mail. Due to the publication of Slim Fizz review in the very popular tabloid, thousands of obese men and women learned about new Slim Fizz diet pills in just a few days.

The readers of Daily Mail online-version have left more than 150 comments to Slim Fizz review and actively distributed information about these diet pills in the popular social networks (Facebook and Twitter as well).

Agiotage around the new weight loss product – Slim Fizz was caused by the fact that the author of the review claims that Slim Fizz provides incredibly rapid weight loss. In the Slim Fizz review published in Daily Mail, one can familiarize with a “success story”, as well as pictures of women “before” and “after” Slim Fizz use.

The author of the review claims that Slim Fizz tablets helped to reduce weight by 5lb in just 10 days. Pictures “before” and “after” using Slim Fizz (after weight loss program) demonstrate that the author of the Slim Fizz review really managed to lose weight significantly.

The manufacturer of Slim Fizz claims that this weight loss product helps to “lose” up to 15lb in just 3 months. Unfortunately, the manufacturer of Slim Fizz cannot guarantee that body weight will not increase again after the end of weight loss program.

How does Slim Fizz work?

slim-fizzSlim Fizz effervescent tablets include active substance Glucomannan (alternative name: konjac mannan). Glucomannan is a natural soluble fibre, which well absorbs moisture.

Under the influence of moisture, the amount of glucomannan fibers increases and they are transformed into high-viscosity jelly-like mass. Glucomannan is gradually transformed into jelly within a few minutes after contact with water.

Due to the ability of glucomannan to swell, to increase in volume and to expand in the stomach, it stimulates the feeling of satiety after the oral use.

The uniqueness of Slim Fizz tablets is in that they should be dissolved in water before using. The use of dissolved Slim Fizz tablets eliminates the probability that glucomannan dietary fibers will swell in the esophagus and cause suffocation.

Unlike other glucomannan-containing weight loss products, Slim Fizz works directly in the stomach and does not create potential risks to normal breathing.

The manufacturer of Slim Fizz states that this slimming product does not cause side effects. However, comments about the fact that discomfort in the stomach can occur after Slim Fizz use, can be found in the customers’ reviews.

The new Slim Fizz weight loss tablets are manufactured by the British company, On-Group Ltd. The key brand of this company is proto-col. Under the brand proto-col, different weight loss products such as Slim Fizz, Thermo-Lite, Carb-Lite, L-carnitine, Pure Arginine are promoted.

For several weeks, Slim Fizz effervescent slimming tablets were sold on Amazon. Potential buyers of weight loss products had the possibility to buy Slim Fizz online in the UK, U.S., Canada and other worldwide countries.

Obese Britons had the opportunity to choose “next day delivery” of Slim Fizz. However, less than a month after the start of retail sales, the access to Slim Fizz purchase on Amazon was limited.

The manufacturer of Slim Fizz asserts that due to high demand, the entire stock of Slim Fizz was quickly sold out. Herewith, On-Group Ltd continues to take orders for Slim Fizz tablets, but does not clarify delivery terms of this weight loss product.

It should be noted that Slim Fizz is not the only over the counter slimming product containing soluble dietary fibres – glucomannan.

At Canadian pharmacies, glucomannan-containing weight loss products are sold under the brands Fibre & Weight Balance, Slimit, Beslim Slimphin and many others. In the country you live, glucomannan tablets and capsules can be sold under other trade names.

If you decide to buy glucomannan or other weight loss product online, read the terms of payment and delivery before making the order.

Diet pills similar to Acomplia

When some innovative drugs appear on market of prescription weight loss products, absolutely all pharmaceutical company begin studying the molecular formula of these drugs.

Competing pharmaceutical companies study the chemical structure and composition of new diet drugs to create diet pills with similar mechanism of action.

New diet pills are protected by patent within 10-15 years after approval and the beginning of retail sales. Therefore, other diet pills with similar mechanism of action can be approved before the patent expires only if they contain other active ingredient.

acomplia-rimonabantFor instance, in the middle of 2000’s, the new Rimonabant diet pills were approved in Europe. In 2006, these diet pills went on sale under the brand Acomplia. Sanofi-Aventis was the developer and global distributor of Acomplia (Rimonabant) pills.

This pharmaceutical company managed to create the diet pills that did not just suppress the appetite, but also reduced the fatty food cravings. In 2006, many specialists claimed that Sanofi-Aventis did a revolution on the global market of weight loss drugs.

The mechanism of action of Acomplia (Rimonabant) differed from that of any other weight loss drugs, available on the pharmaceutical market in 2006. This fact did not go unnoticed for global pharmaceutical giants.

Thus, some of them (including Pfizer and Merck) announced that they were planning to develop some new diet pills with mechanism of action similar to mechanism of action of Acomplia.

In 2007, Sanofi-Aventis did not get the approval for Rimonabant-containing pills (Zimulti) in the USA, and in 2008, the retail sales of Rimonabant pills were stopped in over 50 countries of the world.

After Acomplia diet pills had been withdrawn from European market because of serious mental side effects, Merck and Pfizer refused to develop new diet drugs similar to Acomplia.

In 2016, several new diet pills including Qsymia, Contrave and Belviq are available in the USA. Clinical studies demonstrate that the benefits of new diet pills outweigh the potential risks for health.

However, it is quite possible that after the estimation of post-marketing studies, one or maybe two new diet pills will be withdrawn from the US market. In addition, in 2008 (only 2 years after the start of retail sales) Acomplia diet pills were withdrawn from the markets in Europe and UK.

Xen-Phen

Xenical has become the first prescription weight loss product, which was sold legally on the Internet. Online sales of Xenical were launched in the USA and dozens of other countries in 1999.

In 1999, a prescription for buying Xenical online was not required. Potential buyers of Xenical were offered just fill in online form and pay Xenical cost by means of credit card.

The manufacturer and online retailers of Xenical claimed that this drug works in the stomach, is not absorbed into the blood and thereby is absolutely safe for the health of obese patients. However, many obesity experts claimed that Xenical pills should not be sold without a prescription.

xenicalSuch statements were reasoned by the fact that patients could buy Xenical online without a prescription and not to inform the doctor, who gave them a prescription for Phentermine. The interaction of Xenical and Phentermine has not been studied, so the potential risks of such drug cocktail were unknown.

Concerns of doctors were caused by that just a few years before the launch of Xenical sales, a resonant story associated with the combined use of Fenfluramine and Phentermine (Fen-Phen) happened in the USA. One of the components of this combination – Fenfluramine caused very serious side effects.

Many US physicians were concerned that just as Fen-Phen; the combination of Xenical and Phentermine (Xen-Phen) could lead to unpredictable negative consequences for the health of obese patients.

However, more than 15 years after the online sales of Xenical it can be argued that such fears proved to be groundless. Indeed, between 1999 and 2016 none of serious cases of negative impact of Xen-Phen on the health of obese Americans has been registered.

Saxenda for weight loss

After Saxenda was approved for weight loss, its popularity began to grow rapidly all over the USA. Saxenda is so popular mostly because this is the only drugs, which is used in the USA for injectable weight loss therapy. All the rest FDA-approved drugs, available on the U.S. market in 2015, are used for oral weight loss therapy.

Saxenda injections are used for weight loss for several months only. Therefore, you can hardly find any positive or negative feedbacks about Saxenda yet. Clinical trials have demonstrated that Saxenda provides a significant weight loss only when used for a long time, within 1-2 years. Thus, the first real feedbacks about Saxenda will appear no sooner than in the beginning of 2016.

It should be noted that Saxenda price without insurance is ten times higher than the prices of other weight loss drugs. Hence, Saxenda weight loss drug will be unavailable for patients without healthcare insurance.

Those people, who want to achieve a significant result using Saxenda, must be ready to take this drug for several years.

• When using only Saxenda for weight loss, the cost of one year weight loss therapy will exceed $10 000 US.
• Insured Americans will have to spend a little more than $350 US per year for Saxenda drug.

Such high price of Saxenda without insurance makes the purchase of this weight loss drug impossible. Therefore, an overwhelming majority of obese Americans will be prescribed cheap anorectic drugs, which prices are much lower than of Saxenda.

Unlike the USA, where anorectic drugs are actively used for weight loss, in EU countries the sale of anorectic drugs (including Phentermine) is prohibited.

The appearance of new Saxenda drug provides new opportunity for overweight European people to lose weight. So it is possible that many Europeans with diagnosed overweight or obesity will want to get a healthcare insurance only to be able to use an innovative Saxenda drug for weight loss.

Today, you can buy Saxenda only in the USA. Saxenda drug is approved for weight loss in EU and UK. Hence, it is possible that in the end of 2015 or beginning of 2016, people can buy Saxenda in the UK and 28 EU Member States.

Saxenda injections are not available online yet. Therefore, it is almost impossible to buy Saxenda online right now. If you decide to buy Saxenda online and Saxenda price on online pharmacy is lower than Saxenda price set by the manufacturer, then you can be certain that such Saxenda purchase offer is a fraud.

Novo Nordisk is an exclusive distributor of Saxenda in 2015-2016. You may find current information on suppliers of Saxenda and other weight loss products in the next reviews.

Regimex Review

Regimex is an anorectic drug approved by the FDA as an obesity treatment in September 2010. In 2015, plastic bottles containing 100 round, pink Regimex diet pills are supplied at the US market.

Each Regimex diet pill contains 25mg or 50mg of anorectic agent – Benzphetamine (as Hydrochloride). The same doses of Benzphetamine are contained in Didrex diet pills that were sold in the USA for several decades.

Regimex is a generic version of Didrex. Correspondingly, just as Didrex, Regimex is sold at the US pharmacies by prescription.

• The manufacturer of Regimex medication is WraSer Pharmaceuticals.
• The owner of marketing authorization for Regimex in the USA is Mikart Pharma.

In late 2012, WraSer Pharma planned to launch retail sale of Regimex in the USA. However, American consumers of weight loss products had the opportunity to buy Regimex only in early 2013.

Regimex is used for weight loss in patients with BMI of 30 and higher. Regimex side effects are the same as that of other amphetamine-like anorectics, including Adipex (Phentermine).

There are no significant differences between Regimex (Benzphetamine) and Adipex (Phentermine). Both these weight loss drugs reduce hunger and help to control appetite.

REGIMEXThe only significant difference between Regimex and Adipex is the price. Adipex is one of the most expensive diet pills available at the US market. Thus, when choosing diet pills, obese Americans compare the price of Adipex and Regimex and then pay attention to the effectiveness and safety of these anorectics.

 
Before comparing Regimex price with the price of other anorectic medications, discuss with your doctor the optimal dose of Regimex and dose of other anorectics.

For example, the doctor may recommend taking Regimex 25mg pills three times per day or instead of Regimex may prescribe Adipex 37.5mg pills that are taken just once daily.

In this case, when comparing the price of anorectics, it is necessary to compare the price of an Adipex 37.5mg pill with the price of three Regimex 25mg pills.

Many US pharmacies provide the opportunity to buy Regimex (Benzphetamine) at a discount. To buy Regimex at discount price, it is necessary to get a coupon from the attending physician or print the coupon for Regimex on the Internet.

The manufacturer of Regimex claims that when buying these diet pills at a discount, the price of a Regimex 25mg package is no more than $15 US. If you want to buy Regimex without a prescription, you can find Benzphetamine-containing drugs on online pharmacies. Just as the US retailers, online pharmacies offer to buy Regimex at a discount (with or without the coupon).

Phentermine in the UK

Phentermine has been available in the United Kingdom for over 30 years now. In 2001, the European Medicines Agency recommended to withdraw Phentermine from the UK market. However, this recommendation was fulfilled partially, and thus overweight British people still have a chance to buy Phentermine these days.

ukIn 2015, people can get Phentermine in the UK legally only in private slimming centers and clinics. NHS GPs do not prescribe Phentermine since in 2001-2002, a strict law was introduced, requiring to withdraw this slimming drug from the UK market .

Given the fact that Phentermine was not approved by NHS, it is impossible to find Phentermine at licensed UK pharmacies. To buy Phentermine in the UK, you need to visit a private slimming clinic and pay for doctor’s service.

The cost of first consultation of a skilled UK doctor specializing on anti-obesity treatment ranges between 20 and 200 GBP. Second consultation can be free of charge or cheaper than the first one.

The first consultation is needed to get not only Phentermine in the UK, but also an optimal weight loss program from a doctor. For a rapid weight loss, it is important to adjust an effective Phentermine dose, taking into account:

• Patient’s age
• History of obesity
• Concomitant risk factors
• Level of physical activity

Next visits to the doctor are needed to assess the efficiency of weight loss program and to make a decision about the appropriateness of further use of Phentermine drug.

The price of Phentermine in the UK is similar to the price of Phentermine in the USA and Australia. Depending on the used Phentermine dose and the cost of weight loss clinic services, the cost of drug anti-obesity therapy for one month in the UK (using Phentermine) varies from 80-150 GBP.

If the doctor prescribed Phentermine in the UK along with physiotherapeutic procedures or psychotherapy, the costs of anti-obesity therapy might exceed 150 GBP per month.

To reduce the costs of weight loss therapy, patients need to find a cheap UK weight loss clinic, which offers their clients to buy Phentermine in the UK at low price.

If you want to buy cheap Phentermine in the UK, you can learn the reviews about various slimming clinics and centers where doctors prescribe their patients Phentermine pills.

You can find on different online forums some reviews about slimming centers, as well as distributors (suppliers) of cheap Phentermine. Many UK suppliers of Phentermine have no marketing authorization for this slimming drug. Therefore, they supply Phentermine in the UK through online pharmacies.

You can buy Phentermine on the UK online pharmacy using MasterCard or any other international payment system. Before you purchase Phentermine online in the UK, you need to make sure the supplier has got the UK authorization for Phentermine-containing drugs.

Typharm Limited is one of the few licensed suppliers of Phentermine in the UK in 2015. Phentermine pills by Typharm are sold in the UK under the brand name Ionamin.

Phentermine in sports

Besides success stories, Phentermine can cause frustration stories. Many cases of accidental or intentional use of Phentermine, because of which an athlete has problems in sports, are annually registered in the USA.

One of the most resonance cases of “successful” Phentermine use occurred in 2007. NBA player Lindsey Benson Hunter, Jr. was disqualified for 10 games because doping test confirmed the presence of Phentermine psychostimulant in his body.

426267Lindsey Hunter stated that his wife is taking Phentermine and he took this CNS stimulant accidentally instead of cold medicine. However, this statement did not affect the decision on his disqualification.

According to the terms of U.S. anti-doping program, in primary detection of Phentermine in the athlete’s body, he is automatically disqualified for 10 games. In repeated use of Phentermine or other psychostimulants as doping, Anti-Doping Agency may decide about lifetime suspension of the athlete from his sport.

For example, the US cyclist Duane Dickey received a one-year suspension in 2002 for the use of Phentermine. In 2010, Duane Dickey repeatedly violated anti-doping rule, received lifetime period of ineligibility and was forced to complete his professional sport career.

Duane Dickey is not the only cyclist for whom Phentermine was not the success story, but the story of frustration.

• In November 2004, 2-year period of ineligibility was received by the cyclist Chelsea Redwood because of Phentermine use. As Chelsea stated, she did not know that Phentermine is a doping, but this statement did not affect the decision of the U.S. Anti-doping Agency.

• In May 2005, the similar story was happened with the cyclist Randy Dreyer. Besides the fact that he was disqualified for two years, his sport results and achievements were canceled.

• One of the last US cyclists for whom a success story has been transformed into a story of defeat was Yoelkis Aira. Because of Phentermine use before competitions, Aira accepted a two-year period of ineligibility. Just as Randy Dreyer, Yoelkis Aira was deprived of all points, medals and sport awards received in previous years.

Before to start using Phentermine, professional athletes should be cautioned about the fact that this psychostimulant can put an end to their successful career.

So that Phentermine helps to create a real success story without the potential risks for sport career, the use of Phentermine pills should be discontinued a few month before the competition.

If you have used Phentermine and now you want to tell your story of successful weight loss, you can leave your review about Phentermine on this blog or on popular obesity forums. Leaving your reviews about Phentermine, you help other people to make a step towards a slim figure.

Phentermine by Olon

olon_spaIn most European countries, the sales of Phentermine-containing drugs were discontinued in early 2000’s. But some European pharmaceutical companies are still producing Phentermine anorexigenic agent, exporting it to other countries of the globe.

An Italian-based company, called Olon S.p.A. (part of Fidia Pharma) is one of the European producers of Phentermine in 2015. This pharmaceutical company is a world leading manufacturer of active pharmaceutical ingredients (APIs), including of Phentermine anorectic drug.

Olon does not produce readymade forms, containing Phentermine. Therefore, it does not own the license for wholesale and retail sales of Phentermine-containing diet pills, cooperating with manufacturers of anorectic weight loss products only.

In addition to Phentermine, Olon produces some other anorexigenic agents, some of which are exported to the USA. The list of anorexigenic agents, produced by Olon includes the following active ingredients:

• Benzphetamine HCl (Didrex*)
• Phendimetrazine HCl (Obex LA, Bontril*)
• Clobenzorex HCl (Asenlix, Benturex, Dinintel*)
• Phentermine HCl (Ionamin, Adipex, Duromine*)
• Diethylpropion HCl (Neobes, Tenuate, Regenon*)

*Trade names of weight loss drugs.

There is no information on pharmaceutical companies, using anorexigenic agents by Olon to produce diet pills. You may find the information on other manufacturers of Phentermine, Phendimetrazine, Benzphetamine, Clobenzorex and Diethylpropion anorexigenic agents in previous and following reviews.

Oliver Stone and Phentermine

Phentermine anorexigenic drug is mentioned in the news and life stories of American celebrities from time to time. Most often, Phentermine is found in the news, unfortunately in a negative context and only few times, Phentermine was mentioned as an essential part of a history of success.

The most resonant case, associated with Phentermine and celebrity happened over 15 years ago. In 1999, a world famous film director – Oliver Stone was accused for driving a car while drunk.

oliver_stoneBesides the fact that Oliver Stone was driving his car under the influence of alcohol, local police found several prescription psychostimulants including Phentermine and Fenfluramine in his car.

In late 90’s of the last century, the combination of Phentermine and Fenfluramine was used to cure obesity. Overweight Americans were familiar with such combination of the CNS stimulants (Fenfluramine and Phentermine) under a short name Fen-Phen.

At that time, when Fen-Phen was found in Oliver Stone’s car, Phentermine and Fenfluramine combination was banned for use.

The reason why Fen-Phen diet pills for weight loss were banned was that the combination of Phentermine and Fenfluramine had caused serious threat for the cardiovascular system of obese patients.

Besides Fen-Phen, Oliver Stone had in his car some other psychostimulant drugs, including the FDA-approved anti-anxiety agent – Meprobamate and a small dose of hashish.

This unpleasant story ended by that Oliver Stone pleaded guilty and has agreed to undergo drug rehabilitation. Oliver Stone is not the only world famous celebrity, whose name is associated with stimulant drugs. You can find information on other American celebrities and Phentermine in our reviews.